

Rob Glynnne-Jones

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5622285/rob-glynnne-jones-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

8,827
citations

44
h-index

92
g-index

180
ext. papers

10,575
ext. citations

5.8
avg, IF

5.98
L-index

#	Paper	IF	Citations
166	The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer.. <i>Current Treatment Options in Oncology</i> , 2022 , 23, 453	5.4	1
165	Compliance to chemoradiation in squamous cell carcinoma of the anus.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102381	14.4	
164	Chemoradiotherapy for Locally Advanced T3/T4 Rectal Cancer: What Should We Do with Complete Responders? 2021 , 203-222		
163	Interpreting the RAPIDO trial: factors to consider. <i>Lancet Oncology, The</i> , 2021 , 22, e85	21.7	0
162	Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?. <i>Clinical Oncology</i> , 2021 , 33, e540-e552	2.8	3
161	Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2021 , 60, 1308-1316	3.2	2
160	Prevalence of nodal involvement in rectal cancer after chemoradiotherapy. <i>British Journal of Surgery</i> , 2021 , 108, 1251-1258	5.3	1
159	The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer. <i>Lancet Oncology, The</i> , 2021 , 22, e314-e326	21.7	0
158	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 805-816	19.4	10
157	Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. <i>Annals of Oncology</i> , 2020 , 31, 1587-1588 ¹	19.3	1
156	Preoperative radiotherapy for locally advanced rectal cancer during and after the COVID-19 pandemic. <i>British Journal of Surgery</i> , 2020 , 107, e263	5.3	2
155	FOLFOXIRI reintroduction in metastatic colorectal cancer. <i>Lancet Oncology, The</i> , 2020 , 21, 468-469	21.7	2
154	Unintended consequences of treating early rectal cancers for complete clinical response with chemoradiotherapy. <i>Colorectal Cancer</i> , 2020 , 9, CRC15	0.8	
153	Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. <i>Annals of Oncology</i> , 2020 , 31, 1160-1168	10.3	21
152	Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. <i>Annals of Oncology</i> , 2020 , 31, 1376-1385	10.3	15
151	Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 685-694	3	8
150	How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101964	14.4	19

149	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology, The</i> , 2020 , 21, e252-e264	21.7	24
148	UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. <i>European Journal of Cancer</i> , 2020 , 128, 7-16	7.5	9
147	ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4101-4101	2.2	5
146	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020 , 142, 6-16	5.3	8
145	The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 Gy) in rectal cancer - are we too eager for surgery?. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102104	14.4	6
144	NICE guideline for rectal cancer: already out of date. <i>Lancet, The</i> , 2020 , 395, e105-e106	4.0	
143	Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2020 , 33, 287-297	2.3	2
142	Pooled Analysis of external-beam Radiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). <i>European Journal of Cancer</i> , 2019 , 121, 130-143	7.5	5
141	The Management and Prevention of Anal Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 216-225	7.1	11
140	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine, the</i> , 2019 , 7, 523-532	35.1	30
139	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 529-537	18.8	28
138	Should we favour the use of 5 Gy preoperative radiation in rectal cancer. <i>Cancer Treatment Reviews</i> , 2019 , 81, 101908	14.4	11
137	TNT in rectal cancer may not be the new testament?. <i>EclinicalMedicine</i> , 2019 , 16, 4-5	11.3	5
136	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update 2019 , 407-444		
135	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019 , 134, 119-126	5.3	7
134	Definition of the Rectum: An International, Expert-based Delphi Consensus. <i>Annals of Surgery</i> , 2019 , 270, 955-959	7.8	45
133	Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score. <i>Gut</i> , 2018 , 67, 688-696	19.2	80
132	Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 1202-1211	4	25

131	Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. <i>Medical Oncology</i> , 2018 , 35, 59	3.7	5
130	Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. <i>Colorectal Disease</i> , 2018 , 20 Suppl 1, 97-99	2.1	1
129	Radiation Therapy in Anal Cancer 2018 , 1-23		
128	Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. <i>Radiotherapy and Oncology</i> , 2018 , 126, 222-228	5.3	19
127	The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. <i>European Radiology</i> , 2018 , 28, 1512-1519	8	15
126	Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review. <i>Acta Oncologica</i> , 2018 , 57, 1427-1437	3.2	22
125	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). <i>Heliyon</i> , 2018 , 4, e00804	3.6	16
124	Watch and wait in rectal cancer: is it time to subclassify cT3?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 814-815	18.8	2
123	Optimal management of localized rectal cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 696-704	3.6	7
122	Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 91-101	7	31
121	Initial Results from the Royal College of Radiologists PUK National Audit of Anal Cancer Radiotherapy 2015. <i>Clinical Oncology</i> , 2017 , 29, 188-197	2.8	20
120	Interim FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 28-42	7	8
119	Optimal Sequencing of Neoadjuvant Therapies (NAT) in Rectal Cancer: Upfront Chemotherapy vs. Upfront Chemoradiation. <i>Current Colorectal Cancer Reports</i> , 2017 , 13, 154-164	1	3
118	Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 347-356	21.7	81
117	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. <i>Radiology</i> , 2017 , 284, 552-561	20.5	43
116	Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. <i>Lancet Oncology, The</i> , 2017 , 18, e354-e363	21.7	57
115	Current Status of the Watch-and-Wait Policy for Patients with Complete Clinical Response Following Neoadjuvant Chemoradiation in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017 , 13, 17-26	1	1
114	Clinical endpoints in trials of chemoradiation for patients with anal cancer. <i>Lancet Oncology, The</i> , 2017 , 18, e218-e227	21.7	19

113	PARP inhibitors and chemoradiation for rectal cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 389-390	18.8	
112	Looking for the Good, Bad and the Ugly rectal cancers of the twenty-first century – "How to avoid tears when peeling onions". <i>Techniques in Coloproctology</i> , 2017 , 21, 577-579	2.9	1
111	Treatment of the Primary Tumor in Anal Canal Cancers. <i>Surgical Oncology Clinics of North America</i> , 2017 , 26, 73-90	2.7	10
110	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv22-iv40	10.3	627
109	Anal cancer - What is the optimum chemoradiotherapy?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2016 , 30, 641-53	2.5	9
108	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016 , 63, 11-24	7.5	63
107	Influence of body composition profile on outcomes following colorectal cancer surgery. <i>British Journal of Surgery</i> , 2016 , 103, 572-80	5.3	147
106	Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 447-59	19.4	23
105	Complete Response after Chemoradiotherapy in Rectal Cancer (Watch-and-Wait): Have we Cracked the Code?. <i>Clinical Oncology</i> , 2016 , 28, 152-160	2.8	26
104	Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 92-102	7.1	6
103	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. <i>Cancers</i> , 2016 , 8,	6.6	45
102	Background and Current Treatment of Squamous Cell Carcinoma of the Anus. <i>Oncology and Therapy</i> , 2016 , 4, 135-172	2.7	11
101	Drug Combinations in Preoperative Chemoradiation for Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2016 , 26, 211-9	5.5	1
100	The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, E164-E165	4	30
99	Early rectal cancer: opening the door to change. <i>Lancet Oncology</i> , 2015 , 16, 1449-1451	21.7	3
98	Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. <i>Supportive Care in Cancer</i> , 2015 , 23, 3613-23	3.9	31
97	How Should a Multi-disciplinary Team (MDT) Approach the Issue of Non-Operative Management in Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 352-359	1	
96	Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. <i>International Journal of Cancer</i> , 2015 , 137, 212-20	7.5	74

95	Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. <i>Annals of Oncology</i> , 2015 , 26, 463-76	10.3	230
94	Radiotherapy and locally advanced rectal cancer. <i>British Journal of Surgery</i> , 2015 , 102, 1443-5	5.3	5
93	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. <i>BMC Cancer</i> , 2015 , 15, 764	4.8	24
92	The D prefix: toward a reproducible validated alternative end point in rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2015 , 58, 613-6	3.1	4
91	Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2015 , 16, 200-7	21.7	337
90	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1165-76	3.6	98
89	End points in anal cancer: hopes for a common language. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1281-2	2.2	4
88	Current Evidence for Chemotherapy, Chemoradiation, and the Liver-First Approach for the Management of Patients With Rectal Cancer and Synchronous Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 147-156	1	
87	Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. <i>Annals of Oncology</i> , 2014 , 25, 1356-1362	10.3	184
86	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 111, 330-9	5.3	116
85	Reirradiation of locally recurrent rectal cancer: a systematic review. <i>Radiotherapy and Oncology</i> , 2014 , 113, 151-7	5.3	68
84	Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii10-20	10.3	112
83	Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. <i>Annals of Oncology</i> , 2014 , 25, 1616-22	10.3	35
82	Do t3 rectal cancers always need radiochemotherapy?. <i>Recent Results in Cancer Research</i> , 2014 , 203, 95-115		7
81	Anal cancer: are we making progress?. <i>Current Oncology Reports</i> , 2013 , 15, 170-81	6.3	9
80	Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 146-156	1	
79	Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2013 , 17, 675-85	1.3	25
78	Neoadjuvant therapy before surgical treatment. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 45-59.6		7

77	Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial. <i>Lancet Oncology, The</i> , 2013 , 14, 516-24	21.7	433
76	Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). <i>Cancer</i> , 2013 , 119, 748-55	6.4	64
75	Capturing data on colostomy formation in anal cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 164	2.2	4
74	Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers. <i>Colorectal Disease</i> , 2013 , 15, 1232-7	2.1	18
73	Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. <i>Cancer</i> , 2013 , 119, 2391-8	6.4	24
72	Palliative Radiotherapy for Gastrointestinal and Colorectal Cancer 2013 , 177-187		
71	The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2013 , 4, 264-84	2.8	17
70	Challenges in the neoadjuvant treatment of rectal cancer 2013 , 32-46		
69	Commentary on Latkauskas et al. <i>Colorectal Disease</i> , 2012 , 14, 299-301	2.1	1
68	Rectal cancer--the times they are a-changing. <i>Lancet Oncology, The</i> , 2012 , 13, 651-3	21.7	8
67	Radiotherapy and oncology. <i>Radiotherapy and Oncology</i> , 2012 , 102, 161-2; author reply 162	5.3	4
66	To PET or not to PET? That is the question. Staging in anal cancer. <i>Annals of Oncology</i> , 2012 , 23, 2078-2082.	2.3	34
65	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012 , 23, 2479-2516	10.3	984
64	Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol. <i>Radiotherapy and Oncology</i> , 2012 , 103, 341-6	5.3	10
63	Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. <i>Radiotherapy and Oncology</i> , 2012 , 104, 155-60	5.3	20
62	Current treatment of anal squamous cell carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2012 , 26, 1315-50	3.1	17
61	Critical appraisal of the Wait and see Approach in rectal cancer for clinical complete responders after chemoradiation. <i>British Journal of Surgery</i> , 2012 , 99, 897-909	5.3	175
60	Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?. <i>Annals of Oncology</i> , 2012 , 23, 2517-2526	10.3	37

59	Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4004-4004	2.2	26
58	The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4029-4029	2.2	12
57	Neoadjuvant treatment in rectal cancer: do we always need radiotherapy-or can we risk assess locally advanced rectal cancer better?. <i>Recent Results in Cancer Research</i> , 2012 , 196, 21-36	1.5	11
56	Anal Cancer 2011 , 423-450		
55	Locally advanced rectal cancer: a comparison of management strategies. <i>Drugs</i> , 2011 , 71, 1153-77	12.1	23
54	Chemotherapy/chemoradiation in anal cancer: a systematic review. <i>Cancer Treatment Reviews</i> , 2011 , 37, 520-32	14.4	30
53	End a two-edged sword in their hands. <i>Lancet Oncology, The</i> , 2011 , 12, 519-20	21.7	
52	"Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 1488-94	4	43
51	Antiepidermal growth factor receptor radiosensitizers in rectal cancer. <i>Anti-Cancer Drugs</i> , 2011 , 22, 330-40	4.0	9
50	Chemoradiotherapy in anal cancer. <i>Colorectal Disease</i> , 2011 , 13 Suppl 1, 33-8	2.1	3
49	What is the Impact of the Addition of Oxaliplatin to 5-FluorouracilBased Preoperative Chemoradiation in Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2011 , 7, 1-4	1	1
48	One Size Does Not Fit All: Planning Volumes for Radiotherapy in Rectal CancerShould We Tailor Radiotherapy Fields to Stage and Risk?. <i>Current Colorectal Cancer Reports</i> , 2011 , 7, 89-96	1	
47	Anal cancer: an examination of radiotherapy strategies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 79, 1290-301	4	15
46	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v87-92	10.3	80
45	Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). <i>British Journal of Cancer</i> , 2010 , 102, 1123-8	8.7	262
44	Adjuvant chemotherapy for rectal cancer. <i>Annals of Oncology</i> , 2010 , 21, 2443	10.3	11
43	Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?. <i>Acta Oncologica</i> , 2010 , 49, 378-81	3.2	71
42	Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. <i>Annals of Oncology</i> , 2010 , 21, 1743-1750	10.3	131

41	Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?. <i>Acta Oncologica</i> , 2010 , 49, 278-86	3.2	58
40	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , 2010 , 11, 835-44	21.7	1182
39	Suppression of the postoperative neutrophil leucocytosis following neoadjuvant chemoradiotherapy for rectal cancer and implications for surgical morbidity. <i>Colorectal Disease</i> , 2010 , 12, 549-54	2.1	6
38	High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. <i>Brachytherapy</i> , 2010 , 9, 66-70	2.4	30
37	Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 715-21	4	48
36	Are there alternatives to radical surgery in rectal cancer?. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 240-246	1	
35	A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). <i>Journal of Clinical Oncology</i> , 2009 , 27, LBA4009-LBA4009	2.2	19
34	A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). <i>Journal of Clinical Oncology</i> , 2009 , 27, LBA4009-LBA4009	2.2	41
33	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> , 2008 , 19 Suppl 6, vi1-8	10.3	49
32	Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3669-71	2.2	8
31	Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe?. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 692-3		2
30	Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?. <i>Diseases of the Colon and Rectum</i> , 2008 , 51, 10-9; discussion 19-20	3.1	125
29	Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. <i>British Journal of Surgery</i> , 2008 , 95, 1534-40	5.3	97
28	EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 119-26	4	94
27	Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 99-107	4	331
26	Locally advanced rectal cancer: what is the evidence for induction chemoradiation?. <i>Oncologist</i> , 2007 , 12, 1309-18	5.7	33
25	The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of rectal cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2007 , 21, 1049-70	2.5	14
24	A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. <i>British Journal of Cancer</i> , 2007 , 96, 551-8	8.7	44

23	Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5281-6	2.2	50
22	Is the timing of chemotherapy important in patients undergoing preoperative radiotherapy for rectal cancer?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 150-1		
21	Short course continuous, hyperfractionated, accelerated radiation therapy (CHART) as preoperative treatment for rectal cancer. <i>Acta Oncologica</i> , 2006 , 45, 1079-85	3.2	17
20	Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4664-5; author reply 4665-6	2.2	7
19	Alternative clinical end points in rectal cancer--are we getting closer?. <i>Annals of Oncology</i> , 2006 , 17, 1239-48	1.8	75
18	Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?. <i>British Journal of Cancer</i> , 2006 , 94, 363-71	8.7	71
17	The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. <i>Annals of Oncology</i> , 2006 , 17, 361-71	10.3	67
16	A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. <i>Annals of Oncology</i> , 2006 , 17, 50-6	10.3	65
15	USPIO enhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology?. <i>Colorectal Disease</i> , 2006 , 8, 721-721	2.1	4
14	The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. <i>Colorectal Disease</i> , 2006 , 8, 800-7	2.1	64
13	Can I look at my list? An evaluation of a prompt sheet within an oncology outpatient clinic. <i>Clinical Oncology</i> , 2006 , 18, 395-400	2.8	29
12	Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?. <i>International Journal of Colorectal Disease</i> , 2006 , 21, 117-21	3	112
11	Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3528-3528	2.2	38
10	Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 745-52	4	86
9	A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. <i>British Journal of Cancer</i> , 2005 , 93, 993-8	8.7	46
8	Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). <i>Journal of Clinical Oncology</i> , 2004 , 22, 3575-3575	2.2	4
7	Improving chemoradiotherapy in rectal cancer. <i>Oncologist</i> , 2001 , 6 Suppl 4, 29-34	5.7	44
6	A pilot study of continuous, hyperfractionated, accelerated radiotherapy in rectal adenocarcinoma. <i>Clinical Oncology</i> , 1999 , 11, 334-9	2.8	5

5	Is it worth the wait? A survey of patientsPsatisfaction with an oncology outpatient clinic. <i>European Journal of Cancer Care</i> , 1997 , 6, 50-8	2.4	73
4	Anus327-332		
3	Colon and Rectum308-326		
2	Anus327-332		
1	Colon and rectum308-326		1